ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2023 Earnings Call Transcript March 15, 2024
ProPhase Labs, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.27. PRPH isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Noella Alexander-Young: Hello, and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for ProPhase Labs' Fourth Quarter and Year-End 2023 Results. ProPhase is trading on the Nasdaq under the ticker symbol PRPH. Presenting today is Ted Karkus, Chief Executive Officer. Following the presentation is a question-and-answer session for which you can participate using the Chat box on the top right-hand corner of your screen. With that being said, I will now hand the floor over to Ted.
Ted Karkus: Thank you, Noella, and thank you everyone for joining today for our -- I guess this is called the year-end, even though, we're about to start the second quarter of the following year. We're doing things a little differently today. For those of you that don't know, we have this fantastic relationship with Renmark Financial, and we do non-deal roadshows, virtual non-deal roadshows regularly with Renmark; we have for quite some time. We think it's a great format. And this way, I can show all of you slides and talk through them. I think it's a much better format. After the call, you can let me know if you like the old format better where it's talking, but you don't see me and you don't see the slides. So, in any event, if you want to be updated regularly, we do -- at least once a month, we'll do a virtual non-deal roadshow presentation with Renmark, with Noella.
Noella is our fantastic moderator. I always love having her by my side. We will -- I'll do about a 30-minute presentation, and then we'll have about a 30-minute Q&A. If you have questions, please submit your questions to Noella, and I'll get to as many questions as possible. I hope to have a lively Q&A, so please don't hesitate to send your questions in. I often forget to say things in the presentation, but it all comes out in the Q&A. So with that, I'd also like to highlight just very quickly, we also have a fantastic relationship with ThinkEquity, our investment bankers, who we have had a three-and-a-half-year relationship with. They raised a bunch of capital for us three years ago, but they were also instrumental in helping us to buy additional -- make additional acquisitions that are now going to bear fruit as we go forward.
That's what I'm going to be getting into in today's call. Also appreciate H.C. Wainwright, who follows us on an analytical basis. They do excellent research as well as Diamond Equity Research. And the latest to the table, Dave Gentry at RedChip, just to call out. They're creating some fantastic PR, which is going to bring great brand awareness, not only to ProPhase Labs, the public company, but also to Nebula Genomics. So, I think it's going to be a win-win, and I think you're going to start to see that in the coming weeks. You're going to start to see, amongst other things and different initiatives that include some presence on CNBC. And so, I'm really excited for what's to come. And so, with that, let's get into the presentation. So first, of course, forward-looking statement.
I'm sorry I have to read this. At least our attorneys this year gave me a shorter version. Before we get started, I'd like to remind you of the company's safe harbor language. During this presentation, we will make forward-looking statements, including statements regarding our strategies, plans, objectives, and initiatives, and underlying assumptions. While we believe that these forward-looking statements are reasonable as and when made, forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment and the risk factors listed from time to time in our filings with the SEC filings.
See also 15 Most Powerful Militaries in Latin America and 16 Strongest Navies in the World in 2024.
To continue reading the Q&A session, please click here.
